ArticleFrontiers in pharmacology2026
The PCNA inhibitor AOH1996 impairs tumor growth and invasiveness in non-small cell lung cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide, with a 5-year survival rate of less than 10% in advanced or metastatic disease. AOH1996 is a novel small molecule inhibitor of cancer-associated Proliferating Cell Nuclear Antigen (PCNA). It disrupts DNA replication and repair by enhancing PCNA-RPB1 interactions, dissociating PCNA from transcribed chromatin, and inducing DNA double-strand breaks (DSBs), resulting in selective toxicity of various cancer types. The anticancer effects of AOH1996 on LC remain unclear. Methods: In this study, the anticancer effect of AOH1996 was first examined on four non-small cell lung cancer (NSCLC) cells, namely, A549, LNM35, NCI-H358, and NCI-H460 cell lines using cellular viability assay. Subsequent Results: We demonstrated that AOH1996 significantly decreased NSCLC cells viability and colony growth Conclusion: Our findings highlight AOH1996 as a promising therapeutic agent for NSCLC management, with potent effects on cell survival, migration, invasion, and tumour growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.